SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.

Objective: To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments.

Methods: Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome.

Temporal trends in the incidence and prevalence of Multiple Sclerosis in the Northwest of Spain.

Background: During the last decades, the frequency of multiple sclerosis (MS) is increasing worldwide. Nevertheless, the higher sensibility of the new diagnostic criteria obscures the comparison between studies performed in different decades.

Methods: The evolution of the frequency of MS in Santiago de Compostela (North-West of Spain) between 2003 and 2015 was analyzed using Poisson regression.

Efficacy and safety of fampridine for walking disability in multiple sclerosis.

Fampridine is the only drug approved for the treatment of walking impairment in multiple sclerosis. Around a third of the patients on treatment obtained an improvement in walking speed during the development phase. The effects are clinically significant, appear soon after the start of the treatment and are long-lasting, but disappear soon after the drug is withdrawn.

Epidemiology of multiple sclerosis in Santiago de Compostela (Spain).

Objectives: To analyze the frequency and demographic characteristics of multiple sclerosis (MS) in the Council of Santiago de Compostela (SPAIN).

Material And Methods: The patients diagnosed with MS according to the McDonald 2010 diagnostic criteria were identified within the population of the District of Santiago de Compostela. Several sources were used (records and databases from Hospital, General Practitioners, Private Clinics, and the MS Patients Association).

Clinical response and tolerability of fampridine in clinical practice.

Background: Gait disorder is very prevalent in multiple sclerosis. After 15 years of disease progression, 50% of patients need assistive devices for walking.

Materials & Methods: We performed a multicenter observational study, including multiple sclerosis patients with an Expanded Disability Status Scale score between 4.

Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Aim: To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy.

Patients And Methods: We retrospectively recorded demographic and clinical data, as well as the corpus callosum index (CCI) using MRI, in MS patients treated with natalizumab for 1-4 years.

Results: In the study population (n = 29), baseline mean CCI was 0.